A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, tolerability, and effect on quality of life of
oral capecitabine in combination with intravenous (IV) cisplatin in participants with
metastatic nasopharyngeal cancer. Participants will receive up to 8 cycles of capecitabine
treatment, and cisplatin will be administered on the first day of each cycle. The anticipated
time on study treatment is up to 24 weeks, and the target sample size is 44 individuals.